Literature DB >> 16966395

Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro.

Cécile Ménez1, Marion Buyse, Madeleine Besnard, Robert Farinotti, Philippe M Loiseau, Gillian Barratt.   

Abstract

The aim of this study was to evaluate the potential of a combination of two antileishmanial drugs, miltefosine (HePC) and amphotericin B (AMB), when administered by the oral route. Caco-2 cell monolayers were used as a validated in vitro model of the intestinal barrier and Leishmania donovani promastigotes as a model for evaluating the effect of the drug combination. Spectroscopic measurements demonstrated that HePC and AMB associate, leading to the formation of mixed aggregates in which AMB is solubilized as monomers. The incubation of the association of HePC and AMB with Caco-2 cell monolayers, at a concentration higher than 5 microM, led to (i) a reduction of the HePC-induced paracellular permeability enhancement in Caco-2 cell monolayers, (ii) an inhibition of the uptake of both drugs, and (iii) a decrease in the transepithelial transport of both drugs, suggesting that a pharmacokinetic antagonism between HePC and AMB could occur after their oral administration. However, the combination did not exhibit any antagonism or synergy in its antileishmanial activity. These results demonstrated a strong physicochemical interaction between HePC and AMB, depending on the concentration of each, which could have important consequences for their biological activities, if they are administered together.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966395      PMCID: PMC1635231          DOI: 10.1128/AAC.00837-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

Review 1.  Antiprotozoal activities of phospholipid analogues.

Authors:  Simon L Croft; Karin Seifert; Michael Duchêne
Journal:  Mol Biochem Parasitol       Date:  2003-02       Impact factor: 1.759

2.  Effect of aggregation of amphotericin B on lysophosphatidylcholine micelles as related to its complex formation with cholesterol or ergosterol.

Authors:  M Kawabata; M Onda; T Mita
Journal:  J Biochem       Date:  2001-05       Impact factor: 3.387

3.  Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.

Authors:  Patricia Escobar; Sangeeta Matu; Cláudia Marques; Simon L Croft
Journal:  Acta Trop       Date:  2002-02       Impact factor: 3.112

4.  Circular dichroism study of interactions of Fungizone or AmBisome forms of amphotericin B with human low density lipoproteins.

Authors:  Joanna Barwicz; Marc Beauregard; Pierre Tancrède
Journal:  Biopolymers       Date:  2002       Impact factor: 2.505

5.  Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis.

Authors:  R Santangelo; P Paderu; G Delmas; Z W Chen; R Mannino; L Zarif; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Oral miltefosine for Indian visceral leishmaniasis.

Authors:  Shyam Sundar; T K Jha; C P Thakur; Juergen Engel; Herbert Sindermann; Christina Fischer; Klaus Junge; Anthony Bryceson; Jonathan Berman
Journal:  N Engl J Med       Date:  2002-11-28       Impact factor: 91.245

7.  The formation of amphotericin B ion channels in lipid bilayers.

Authors:  G Fujii; J E Chang; T Coley; B Steere
Journal:  Biochemistry       Date:  1997-04-22       Impact factor: 3.162

8.  Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance.

Authors:  F Javier Pérez-Victoria; Francisco Gamarro; Marc Ouellette; Santiago Castanys
Journal:  J Biol Chem       Date:  2003-09-27       Impact factor: 5.157

9.  Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis.

Authors:  Arnold H van der Luit; Marianne Budde; Paula Ruurs; Marcel Verheij; Wim J van Blitterswijk
Journal:  J Biol Chem       Date:  2002-08-14       Impact factor: 5.157

10.  Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

Authors:  Karin Seifert; Sangeeta Matu; F Javier Pérez-Victoria; Santiago Castanys; Francisco Gamarro; Simon L Croft
Journal:  Int J Antimicrob Agents       Date:  2003-10       Impact factor: 5.283

View more
  10 in total

Review 1.  Mechanisms of drug combinations: interaction and network perspectives.

Authors:  Jia Jia; Feng Zhu; Xiaohua Ma; Zhiwei Cao; Zhiwei W Cao; Yixue Li; Yixue X Li; Yu Zong Chen
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

2.  Investigational drugs for visceral leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Investig Drugs       Date:  2014-11-20       Impact factor: 6.206

3.  Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.

Authors:  Virgínia M Carregal; Juliane S Lanza; Daniel M Souza; Arshad Islam; Cynthia Demicheli; Ricardo T Fujiwara; Luis Rivas; Frédéric Frézard
Journal:  Parasitol Res       Date:  2019-08-10       Impact factor: 2.289

4.  Drug combinations as effective anti-leishmanials against drug resistant Leishmania mexicana.

Authors:  Humera Ahmed; Charlotte R Curtis; Sara Tur-Gracia; Toluwanimi O Olatunji; Katharine C Carter; Roderick A M Williams
Journal:  RSC Med Chem       Date:  2020-07-02

5.  SQ109 inhibits proliferation of Leishmania donovani by disruption of intracellular Ca2+ homeostasis, collapsing the mitochondrial electrochemical potential (ΔΨm) and affecting acidocalcisomes.

Authors:  Zain Gil; Nathalia Martinez-Sotillo; Andrea Pinto-Martinez; Fabiola Mejias; Juan Carlos Martinez; Ivan Galindo; Eric Oldfield; Gustavo Benaim
Journal:  Parasitol Res       Date:  2020-01-02       Impact factor: 2.289

Review 6.  Optimizing efficacy of Amphotericin B through nanomodification.

Authors:  Gillian Barratt; Stéphane Bretagne
Journal:  Int J Nanomedicine       Date:  2007

Review 7.  Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments.

Authors:  Daniel Michał Kamiński
Journal:  Eur Biophys J       Date:  2014-08-31       Impact factor: 1.733

8.  Hydrophobicity of Antifungal β-Peptides Is Associated with Their Cytotoxic Effect on In Vitro Human Colon Caco-2 and Liver HepG2 Cells.

Authors:  Camilo Mora-Navarro; Janet Méndez-Vega; Jean Caraballo-León; Myung-Ryul Lee; Sean Palecek; Madeline Torres-Lugo; Patricia Ortiz-Bermúdez
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

9.  Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.

Authors:  Thomas P C Dorlo; Anke E Kip; Brima M Younis; Sally J Ellis; Fabiana Alves; Jos H Beijnen; Simon Njenga; George Kirigi; Asrat Hailu; Joseph Olobo; Ahmed M Musa; Manica Balasegaram; Monique Wasunna; Mats O Karlsson; Eltahir A G Khalil
Journal:  J Antimicrob Chemother       Date:  2017-11-01       Impact factor: 5.790

10.  In vitro effectivity of three approved drugs and their synergistic interaction against Leishmania infantum.

Authors:  Iman Fathy Abou-El-Naga; Rasha Fadly Mady; Nermine Mogahed Fawzy Hussien Mogahed
Journal:  Biomedica       Date:  2020-05-01       Impact factor: 0.935

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.